Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Completed · Phase 3 · NCT06241313
Conditions: Migraine
At a glance
- Research payments reported, 2025
- $5,673
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 2,158
About the trial
- Sponsor
- AbbVie
- Tested
- Atogepant (drug), Placebo for Atogepant (drug)
- Dates
- Started 2024-03-25; completion 2026-08-11
- Results posted
- Not yet
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms. The main goal of the study is to see if atogepant is effective, safe, and well-tolerated in treating migraine attacks quickly. Atogepant is a medicine currently approved for the preventive treatment of migraine in adults and has been shown to be effective and well tolerated when taken daily to prevent migraine attacks. This study includes double-blind phase means that neither the participants nor the study doctors know who is given which study treatment (atogepant or placebo) followed by…
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $5,673 in research payments for this study in 2025 (3 payments).
Products named: Qulipta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $5,673
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.